Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMET: Metformin with Salvage RT for Prostate Cancer
NCT02945813Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2017
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in prostate cancer (PCa) (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Time to progression at 18 months. Started Oct 2017; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02945813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945813.